Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer’s and cat allergy

[1]  K. Rhodes,et al.  The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease , 2016, Nature.

[2]  G. Jennings,et al.  Development of an Interleukin-1β Vaccine in Patients with Type 2 Diabetes. , 2016, Molecular Therapy.

[3]  J. Koo,et al.  Anti-IL-17 Agents for Psoriasis: A Review of Phase III Data. , 2016, Journal of drugs in dermatology : JDD.

[4]  Martin Bachman,et al.  Beyond passive immunization: toward a nanoparticle-based IL-17 vaccine as first in class of future immune treatments. , 2015, Nanomedicine.

[5]  M. Udey,et al.  IL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms , 2014, Proceedings of the National Academy of Sciences.

[6]  L. Klimek,et al.  Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs , 2014, Expert review of clinical immunology.

[7]  E. Siemers,et al.  Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[8]  K. Salánki,et al.  A Cucumber Mosaic Virus Based Expression System for the Production of Porcine Circovirus Specific Vaccines , 2012, PloS one.

[9]  W. Siess,et al.  The EP3-agonist sulprostone, but not prosta glandin E2 potentiates platelet aggregation in human blood , 2010, Thrombosis and Haemostasis.

[10]  H. Grönlund,et al.  The Major Cat Allergen, Fel d 1, in Diagnosis and Therapy , 2009, International Archives of Allergy and Immunology.

[11]  A. Jegerlehner,et al.  Alveolar Macrophages and Lung Dendritic Cells Sense RNA and Drive Mucosal IgA Responses , 2009, The Journal of Immunology.

[12]  M. Bachmann,et al.  Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy , 2009, The Journal of experimental medicine.

[13]  Z. Amoura,et al.  IFNα kinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model , 2009, Proceedings of the National Academy of Sciences.

[14]  G. Jennings,et al.  Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. , 2009, Annual review of pharmacology and toxicology.

[15]  Martin F. Bachmann,et al.  The coming of age of virus-like particle vaccines , 2008, Biological chemistry.

[16]  H. Volk,et al.  Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study , 2008, The Lancet.

[17]  K. Schwarz,et al.  Efficient induction of mucosal and systemic immune responses by virus‐like particles administered intranasally: implications for vaccine design , 2008, European journal of immunology.

[18]  H. Volk,et al.  A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity , 2007, Journal of hypertension.

[19]  G. Jennings,et al.  Vaccination against IL‐17 suppresses autoimmune arthritis and encephalomyelitis , 2006, European journal of immunology.

[20]  H. Fields,et al.  The nonresponse to hepatitis B vaccination is associated with impaired lymphocyte activation. , 2004, Virology.

[21]  R. Vierkant,et al.  Identification of an association between HLA class II alleles and low antibody levels after measles immunization. , 2001, Vaccine.

[22]  N. Karin,et al.  Augmentation of natural immunity to a pro-inflammatory cytokine (TNF-alpha) by targeted DNA vaccine confers long-lasting resistance to experimental autoimmune encephalomyelitis , 1999, Gene Therapy.

[23]  Ichikawa,et al.  High prevalence of sensitization to cat allergen among Japanese children with asthma, living without cats , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[24]  Y. Vanrenterghem,et al.  A prospective, randomized trial of pretransplant blood transfusions in cadaver kidney transplant candidates , 1994 .

[25]  D. Valmori,et al.  Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination. , 1992, Journal of immunology.

[26]  I. J. Griffith,et al.  Expression and genomic structure of the genes encoding FdI, the major allergen from the domestic cat. , 1992, Gene.

[27]  M. Chapman,et al.  Amino acid sequence of Fel dI, the major allergen of the domestic cat: protein sequence analysis and cDNA cloning. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[28]  G. Nitti,et al.  Studies on the biochemical structure of the major cat allergen Felis domesticus I. , 1991, Molecular immunology.

[29]  Antonio Lanzavecchia,et al.  Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells , 1989, European journal of immunology.

[30]  Y. Vanrenterghem,et al.  A prospective, randomized trial of pretransplant blood transfusions in cadaver kidney transplant candidates. Leuven Collaborative Group for Transplantation. , 1994, Transplant international : official journal of the European Society for Organ Transplantation.